Goofball? People typically resort to name calling when they cannot make a credible argument. Maybe you are short, or maybe you don't understand the dilutive nature of what the CFO is doing, or maybe you just aren't good at math.
The CFO in the last year alone, has PERMANENTLY diluted shareholder value by more than 20%. That's FOREVER. How would you like it if the government suddenly, this year, started taking 20% MORE of your annual salary? FOREVER. So your tax rate goes from 33% to 53%, and it was made permanent. That's what just happened. All future earnings, all profits, etc., will now be diluted by 20% more shares (just from the last year alone).
Whatever. It astounds me you actually invest in the market when you clearly cannot grasp the most simplistic concept. His is why the poor stay poor.
Assuming you are long on SRPT, the CFO just reduced the value of your investment by $225M and when I object to him stealing money from shareholders, you call ME a dope?
Maybe you sold it short, because that's the only one it helps.
$429M in debt and dilutive offering in the past YEAR. Where does it all go?
For a 2.7B company???
The stock keeps getting diluted at every turn. The CFO doesn't raise cash any other way. He is an albatross around the neck of SRPT. SRPT would be FAR better off without that dead weight that actively harms shareholder value.
They know no other way. I would have fired the CFO long ago.
Care to try that again Rico? I was right, you were wrong.
Only a complete jerk would antagonize a woman after she was just raped, but that is exactly what you are doing here now.
Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal
Allergan could pay up to 19 times the value of the liver-disease treatment maker.
Even though Tobira failed to meet the primary endpoint in their lead candidate drug. Allergan paying 19x he current market cap.
Referencing the Seeking Alpha message board is as stupid as referencing this Yahoo message board.
What about ETHICAL sub-therapeutic dosing? Specifically, to ramp a patient up gradually to check tolerance due to that patients u inquest medical needs and situation? Why jump right to unethical? No clinical trial can account for every possible situation for every patient (especially if there were only 12 in the trial).
LOL stock loses 85% of its value and the one post demanding the CEO be held accountable gets a thumbs down. Must have been a short who wants to keep the moron in place.
CFO will probably go back for another secondary offering, like a pig at the trough ...
With the market cap equating to the cash on hand, holding it is basically free at this point.
You don't understand do you? If he stock opens at $1.50 then you trade at that. You'll never get $8.
It is an exceptionally high risk situation. SRPT has many problems, but also meets an unmet need for a devastating illness. The Adcom voted against approval, but the primary obstacle (guy named Farkas) just quit the FDA. Possibly in protest of the FDAs intent to approve Eteplirsen, possibly because that fate was sealed in a CRL and he had completed that task. We won't know for a while longer, but SRPT is exceptionally risky.